Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $15
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $18 to $15.
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $18 to $15.